Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2025 08:30 ET | Source: Dyadic International, Inc.

Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
July 30, 2024 16:00 ET | Source: Dyadic International, Inc.

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
March 28, 2024 08:30 ET | Source: Dyadic International, Inc.

Dyadic Announces Change in Board and Management Leadership Roles

JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
August 11, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
March 09, 2021 08:30 ET | Source: Dyadic International, Inc.

Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting

JUPITER, Fla., March 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...